Job title: Chief Executive Officer
Mr. Elias Papatheodorou brings with him more than 20 years of experience with private and public biotechnology companies, as well as with The Coca-Cola Company and Philip Morris International. As Chief Business Officer of Covagen AG, he was instrumental in the closing of a CHF46 million series B round and the subsequent acquisition of Covagen by Jannsen Pharmaceuticals, a J&J Company. Previously, Elias was Senior Vice President for Operations and Business Development at Medigene AG. Elias has also served for a number of years as the CEO of novosom AG. During his tenure, the Smarticles technology entered clinical trials in the U.S.A., the company raised funds and closed licensing deals. Finally, he engineered the sale of Novosom’s assets to Marina Biotech (MRNA). He received his undergraduate education at Ithaca College, NY, and his graduate education at Cornell University, NY.
Pannel Discussion: Can we Get to Combos? 2:00 pm
day: Day Two